Form 4: Accuray Director Acquires 56,603 Restricted Stock Units

Accuray Inc. Director James M. Hindman was granted 56,603 Restricted Stock Units, vesting in November 2026.

Summary

• James M. Hindman, a Director of Accuray Inc. (ARAY), acquired 56,603 Restricted Stock Units (RSUs) on November 28, 2025.
• Each RSU represents a contingent right to receive one share of Accuray's common stock.
• The RSUs have a conversion or exercise price of $0, typical for such grants.
• The entire grant of 56,603 RSUs is scheduled to vest 100% on November 13, 2026.
• Following this transaction, Mr. Hindman beneficially owns 56,603 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive sign of continued alignment and commitment, though it's a routine compensation event rather than a significant operational or financial announcement that would drastically alter sentiment.

Positives

• Director James M. Hindman received 56,603 Restricted Stock Units, which aligns his interests with long-term shareholder value.
• The grant of RSUs is a standard form of director compensation, indicating continued commitment and retention.

Risks

• The ultimate value of the Restricted Stock Units is directly tied to the future market price of Accuray Inc. common stock.
• There is a risk that the company's stock price could decline before the vesting date, which would reduce the value of this compensation.

Future Outlook

The grant of Restricted Stock Units with a future vesting date indicates a long-term incentive for the director, aligning their future compensation with the company's performance through the vesting period.

Industry Context

The grant of Restricted Stock Units is a standard practice in the medical technology and healthcare industry for compensating directors and executives. This method aims to align their interests with long-term shareholder value and promote retention within the company.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a compensation mechanism for directors is a common practice across various industries, including medical technology, aligning director incentives with long-term company performance.
• The vesting schedule, with 100% vesting on a future date, is typical for RSU grants, promoting retention and sustained focus on company growth, consistent with industry benchmarks for executive and director compensation.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns management's interests with long-term shareholder value, as the value of the compensation is tied to the company's stock performance.
• Employees: This filing does not directly impact general employees, but it reflects standard compensation practices for leadership within the company.

Next Steps

• The Restricted Stock Units are scheduled to vest on November 13, 2026, at which point they will convert into shares of Accuray Inc. common stock.

Key Dates

Recommendation

This Form 4 reports a routine grant of Restricted Stock Units to an existing director as part of their compensation. While it signifies continued alignment of interests, it does not provide new fundamental information about the company's operational or financial performance that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals.

Keywords

Accuray, ARAY, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Form 4, Equity Grant, James M. Hindman